Literature DB >> 22320029

Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting.

James Brown1, Beatrice Setnik, Keung Lee, Linda Wase, Carl L Roland, Jody M Cleveland, Sherry Siegel, Nathaniel Katz.   

Abstract

OBJECTIVES: To evaluate potential for and incidence of aberrant drug-related behaviors among patients with chronic, moderate-to-severe pain in a primary care setting and to determine investigator compliance with universal precautions (UP) approach to pain management.
DESIGN: Open label, multicenter.
SETTING: Primary care centers (N = 281) across the United States. PATIENTS: Opioid naïve and opioid experienced with chronic, moderate-to-severe pain (N = 1,487).
INTERVENTIONS: Morphine sulfate extended-release capsules for < or = 4 months. Tools comprising UP approach were treatment agreement, card for obtaining/tracking prescriptions, Screener and Opioid Assessment for Patients with Pain-Revised questionnaire, pill counts, pain-patient follow-up tool, investigator assessment/plan, and urine drug screens (UDSs). OUTCOME MEASURES: Proportion of patients at low, moderate, and high risk of opioid misuse/abuse based on prespecified criteria and investigator judgment, proportion of patients with aberrant drug-related behaviors, and proportion of investigators compliant with UP approach.
RESULTS: Patients were primarily white (87 percent), women (57 percent); mean age, 53 years (range, 21-92years). At baseline, 47 percent were considered low risk for opioid misuse/abuse, 52 percent moderate, and 1 percent high. UDSs were positive for illicit/nonprescribed drugs in a proportion of patients throughout the study. Overall, 64 percent of investigators were compliant with major components of UP approach in > or = 75 percent of their patients. However, there was a tendency for investigators to assign risk levels for opioid misuse/abuse as lower than protocol specified.
CONCLUSIONS: Most patients in these primary care study centers were categorized as at least moderate risk for opioid misuse/abuse at baseline. Most primary care investigators complied with the UP approach to pain management and risk assessment. The completion of the brief training and clinical use of the tools during the study led to retained behavior change, but there was a tendency for investigators to assign lower risk levels than those that were protocol-specified, suggesting a need for better understanding of factors influencing investigator decisions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22320029     DOI: 10.5055/jom.2011.0088

Source DB:  PubMed          Journal:  J Opioid Manag        ISSN: 1551-7489


  5 in total

Review 1.  Current topics in opioid therapy for pain management: addressing the problem of abuse.

Authors:  Frank E Casty; Matthew S Wieman; Neil Shusterman
Journal:  Clin Drug Investig       Date:  2013-07       Impact factor: 2.859

Review 2.  A Systematic Review of Opioid and Benzodiazepine Misuse in Older Adults.

Authors:  Rachel D Maree; Zachary A Marcum; Ester Saghafi; Debra K Weiner; Jordan F Karp
Journal:  Am J Geriatr Psychiatry       Date:  2016-06-07       Impact factor: 4.105

3.  At-a-glance - The local response to the Canadian opioid epidemic in the Kingston, Frontenac, and Lennox and Addington communities.

Authors:  Anees Bahji; Daenis Camiré
Journal:  Health Promot Chronic Dis Prev Can       Date:  2019-12       Impact factor: 3.240

4.  Effectiveness and safety of morphine sulfate extended-release capsules in patients with chronic, moderate-to-severe pain in a primary care setting.

Authors:  James Brown; Beatrice Setnik; Keung Lee; Jody M Cleveland; Carl L Roland; Linda Wase; Lynn Webster
Journal:  J Pain Res       Date:  2011-11-08       Impact factor: 3.133

5.  A multicenter, primary care-based, open-label study to identify behaviors related to prescription opioid misuse, abuse, and diversion in opioid-experienced patients with chronic moderate-to-severe pain.

Authors:  Beatrice Setnik; Carl L Roland; Kenneth W Sommerville; Glenn C Pixton; Robert Berke; Anne Calkins; Veeraindar Goli
Journal:  J Pain Res       Date:  2015-07-09       Impact factor: 3.133

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.